Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Thoracic 2Sarcoma 1Lymphoid 1Gynecologic 1

Conditions

Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1

Interventions

Specimen Handling 14Magnetic Resonance Spectroscopy 14Cyclophosphamide 10Doxorubicin 8Biopsy 8atezolizumab 7X-Rays 7Radiation 7Temozolomide 6Nivolumab 6fludarabine 5Vincristine 5Radiotherapy 5Phantoms, Imaging 5Etoposide 5Bevacizumab 5pembrolizumab 4cabozantinib 4anlotinib 4Sirolimus 4Nuclear Medicine Department, Hospital 4Irinotecan 4Immunoglobulin G 4Ifosfamide 4Disulfides 4palbociclib 3olaparib 3liposomal doxorubicin 3fludarabine phosphate 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vinorelbine × Sarcoma × 30 days × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡